(The 3rd CIIE) Well-known pharmaceutical companies join hands with Chinese partners to inject vitality into the new "dual cycle" pattern
China News Online, November 6th (Reporter Chen Jing) Novo Nordisk and Microsoft are working with Microsoft to improve people’s awareness of diabetes; Novartis and WeDoctor build a model of “integrated diagnosis and treatment of specialized diseases”; Pfizer and medical schools jointly promote medical Anti-cooperation; Boehringer Ingelheim assists the Chinese Stroke Society to promote standardized and standardized stroke diagnosis and treatment procedures...
At the 3rd CIIE, which is being held on the 6th, the medical equipment and medicine and health care exhibition area is particularly lively. The world-renowned pharmaceutical companies "Sing it, I will appear on the stage", and continue to sign contracts. While helping to improve the construction of China's public health system, Inject vitality into the "dual cycle" new economic structure.
Novartis Pharmaceuticals (China), a pharmaceutical and healthcare company headquartered in Switzerland, launched Biome, a Chinese business innovation alliance.
Photo courtesy of Swiss company Novartis
The new crown pneumonia epidemic sweeping the world has made people deeply aware of the preciousness of health and more pursuit of the quality of life.
Novo Nordisk, a biopharmaceutical company headquartered in Denmark, and Microsoft have jointly developed an intelligent question-and-answer robot for diabetes science knowledge that can provide all-Chinese services. It hopes to help more Chinese patients improve their knowledge of diabetes and manage their lives more scientifically and effectively.
Zhou Xiaping, senior vice president and president of Novo Nordisk's Greater China Region, said: “The research and development of new drugs is certainly the main contribution of innovative drug companies, and it is more important for industry partners to gather the power of everyone to expand the ecosystem of'change diabetes'.” Microsoft Ke Ruijie, chairman and CEO of Greater China, believes that nowadays, all walks of life are accelerating the pace of digital transformation and responding to the impact of the epidemic with technological innovation.
He hopes that Microsoft's technology can help companies improve their innovation capabilities.
"During the interview, the reporter learned that in the field of medical + artificial intelligence, both parties will work hard for a long time to gather advantages and set a new benchmark for AI-enabled chronic disease management.
Novartis Pharmaceuticals (China), a pharmaceutical and healthcare company headquartered in Switzerland, has launched the China Business Innovation Alliance Biome, which will break the industry boundaries and accelerate the implementation of innovative digital medical solutions with all parties.
Novartis Global Chief Digital Officer Bertrand Bodson told reporters: “Novartis Biome will gather top technology resources and leverage each other to provide more valuable and influential healthcare solutions.” According to Zhang Ying, President of Novartis Pharmaceuticals (China), digitalization It is an important starting point for optimizing the management of the entire treatment course of patients, improving the experience of patients' medical treatment and long-term disease management in the future.
Pfizer and Xiehe Qun Public College have joined hands to advance medical and prevention collaboration.
Pfizer Biopharmaceutical Group
As Biome's first landing project in China, Novartis Pharmaceuticals (China) and WeDoctor Group signed a "Memorandum of Strategic Cooperation" to jointly explore a new model of digital health management.
Ankylosing spondylitis has become the first specialized disease field to be entered. Both parties will use digital solutions to deal with the challenges and create a suitable "specialized disease integration" diagnosis and treatment model.
The new crown epidemic that has swept the world this year has made people fully aware of the importance of building a public health system.
Pfizer Biopharmaceutical Group, headquartered in New York, USA, signed a contract with the Chinese Academy of Medical Sciences and Peking Union Medical College School of Medicine and Public Health (referred to as Xiehe Public School) on the 6th to launch a three-year strategic cooperation to promote medical and prevention coordination.
The two sides will carry out academic exchanges and discuss the promotion of the construction of the chief public health physician system, the alliance for the prevention and treatment of pneumococcal diseases, and the construction of innovative vaccines and drug application research centers.
Yang Weizhong, Executive Dean of Xiehe Qun Public College, said: "I believe that the cooperation with Pfizer will help the implementation of the medical and prevention concept, promote multidisciplinary innovative research and the transformation of results, and cultivate outstanding public health talents."
The new crown epidemic has increased the public's attention to lung health.
Cao Junyang, head of medicine in China of Pfizer Biopharmaceutical Group, said that he hopes to cooperate with Chinese medical and health professionals, the government and the community to keep the vaccination rate of the national immunization program for school-age children at a high level.
On the same day, the German pharmaceutical company Boehringer Ingelheim and the Chinese Stroke Society formally signed the "Memorandum of Cooperation" to deepen strategic cooperation in the field of stroke.
The two parties will give full play to their respective resource advantages, advance the "Stroke Comprehensive Training Center Project" and start the construction of the Sichuan (Chengdu) Comprehensive Stroke Training Center to reduce the fatality rate and disability rate of stroke in China as much as possible.
Professor Lu Dehong, vice president of the Chinese Stroke Society, said bluntly: "The quality of stroke treatment services in China is uneven, and it takes a long time to promote the construction of comprehensive stroke training centers in various regions." This strategic cooperation will benefit the rapid development of stroke disease management.
Dong Bowen, head of Boehringer Ingelheim's Greater China Human Medicines Division, hopes to build a comprehensive stroke training center in Sichuan (Chengdu), which will radiate the western region and improve the level of treatment of clinicians.
He also hopes to comprehensively promote standardized and standardized stroke diagnosis and treatment processes to benefit Chinese patients.
The third CIIE held as scheduled under the normalization of COVID-19 prevention and control highlights China's sincere desire to share market opportunities with the world and promote the recovery of the world economy.
The CIIE is also an important window to build a "domestic and international dual cycle" pattern.
Bayer Group, a life science company, revealed to reporters that during the CIIE, it will sign contracts with a number of Chinese companies and join hands with China's pharmaceutical industry groups, innovative companies and biotechnology companies to inject more vitality into the new economic structure of the "double cycle".
Bayer told reporters on the same day that it looks forward to working with Chinese companies to improve the availability of products in China, fully develop innovative results, accumulate energy to stimulate the internal circulation, promote the external circulation, and benefit more Chinese consumers.
(Finish)